GlassScriptPhysician profile
David R Haromy
NPI 1265402556
$7,768.49
in general payments reported to CMS, 2019-2025
40 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,238 · 2022: $1,293 · 2023: $1,692 · 2024: $1,819 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,137.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,151.61 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $706.17 | 2021-2025 | Livdelzi, Epclusa, Trodelvy |
| Neurocrine Biosciences, INC. | $358.81 | 2023-2025 | Ingrezza |
| Genentech USA, INC. | $342.03 | 2021-2023 | Evrysdi |
| Genzyme Corporation | $312.49 | 2021-2025 | |
| Biogen, INC. | $301.72 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $242.06 | 2023-2025 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $233.66 | 2021-2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $231.09 | 2024-2025 | Austedo Xr |
| Viiv Healthcare Company | $228.66 | 2022 | |
| Abiomed | $228.52 | 2025 | |
| Paratek Pharmaceuticals, INC. | $226.49 | 2022-2023 | Nuzyra |
| Astellas Pharma US INC | $223.14 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $210.04 | 2024-2025 | Arexvy |
| Kyowa Kirin, INC. | $128.92 | 2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haromy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.